Philippe N. Bolduc,Magnus Pfaffenbach,Ryan Evans,Zhili Xin,Kate L. Henry,Fang Gao,Terry Fang,John Silbereis,Jorge Vera Rebollar,Pei Li,Jayanth V. Chodaparambil,Claire M. Metrick,Emily A. Peterson
We herein report the discovery, synthesis, and evolution of a series of indazoles and azaindazoles as CNS-penetrant IRAK4 inhibitors. Described is the use of structure-based and property-based drug design strategically leveraged to guide the property profile of a key series into a favorable property space while maintaining potency and selectivity. Our rationale that led toward functionalities with potency improvements, CNS-penetration, solubility, and favorable drug-like properties is portrayed. In vivo evaluation of an advanced analogue showed significant, dose-dependent modulation of inflammatory cytokines in a mouse model. In pursuit of incorporating a highly engineered bridged ether that was crucial to metabolic stability in this series, significant synthetic challenges were overcome to enable the preparation of the analogues.